CD274 and head and neck squamous cell carcinoma: Contrarily to FDA, EMA approved the immunotherapy in HNSCC regardless of the test (antibody and IHC platform) used, introducing the problem of harmonization between different types of antibodies and IHC platforms for evaluating the expression of PD-L1 with CPS in HNSCC [82,83].